Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5946-5960

  Louie, Arnold ^a   VanScoy, Brian ^a,b   Liu, Weiguo ^a   Kulawy, Robert ^a,c   Drusano, G L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ICPD   (United States)

^c ICON Development Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BETA LACTAMASE; DICLOXACILLIN; ANTIINFECTIVE AGENT;

ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERICIDAL ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; HOLLOW FIBER; HUMAN; IN VITRO STUDY; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MUTATION RATE; NONHUMAN; OUTCOME ASSESSMENT; POST EXPOSURE PROPHYLAXIS; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; BACTERIAL COUNT; CHILD; COMPUTER SIMULATION; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HALF LIFE TIME; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREGNANCY; STATISTICAL MODEL;

AMOXICILLIN; ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BETA-LACTAMASES; CHILD; COLONY COUNT, MICROBIAL; COMPUTER SIMULATION; DICLOXACILLIN; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; GENE EXPRESSION; HALF-LIFE; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MONTE CARLO METHOD; PREGNANCY;

EID: 84887427929     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02616-12     Document Type: Article

References (38)

1. Inglesby T, O'Toole T, Henderson DA, Bartlett JG, Ascher S, Eitzen E, Friedlander AM, Gerberding J, Hauser J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K, Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
2. Quinn C, Trunbull P. 1998. Anthrax, p 799-818. In Collier L, Balows A, SussmanM(ed), Topley and Wilson's microbiology and microbial infections, 9th ed. Oxford University Press, New York, NY.
3. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 266:1202-1208.
4. Brachman P, Friedlander A. 1994. Anthrax, p 729-739. In Plotkin S, Mortimer E (ed). Vaccines. WB Saunders, Philadelphia, PA.
5. Wright JG, Quinn CP, Shadomy S, Messonnier N, Centers for Disease Control and Prevention. 2010. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recommend. Rep. 59(RR-6):1-30.
6. Korzeniowski OM. 1995. Antibacterial agents in pregnancy. Infect. Dis. Clin. North Am. 9:639-651.
7. Woods JB. 2005. Antimicrobial for biological warfare agents, p 285-315. In Linder LE, Lebeda FJ, Korch GW (ed), Biological weapons defense: infectious diseases and counterterrorism. Humana Press, Inc., Totowa, NJ.
8. Lochary ME, Lockhart PB, Williams WT, Jr. 1998. Doxycycline and staining of permanent teeth. Pediatr. Infect. Dis. J. 17:429-431.
9. Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M. 2007. Absence of tooth staining with doxycycline treatment in young children. Clin. Pediatr. 46:121-126.
10. Center for Drug Evaluation and Research. 17 December 2001. Commentary on non-labeled dosing of oral amoxicillin in adults and pediatrics for post exposure inhalational anthrax. http://www.fda.gov/Drugs/EmergencyPreparedness/ BioterrorismandDrugPreparedness/ucm072106.htm.
11. Andrew MA, Easterline TR, Carr DB, Shen D, Buchanan ML, Rutherford T, Bennett R, Vicini P, Hebert MF. 2007. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin. Pharmacol. Ther. 81:547-556.
12. Chamberlain A, White S, Bawdon R, Thomas Larsen B. 1993. Pharmacokinetics of ampicillin and sulbactam in pregnancy. Am. J. Obstet. Gynecol. 168:667-673.
13. Cono J, Cragan JD, Jamieson DJ, Rasmussen SA. 2006. Prophylaxis and treatment of pregnant women for emerging infections and bioterrorism emergencies. Emerg. Infect. Dis. 12:1631-1637.
14. Heikkela AM, Erkkola RU. 1993. The need for adjustment of dosage regimen of penicillin V during pregnancy. Obstet. Gynecol. 81:919-921.
15. Schneider H. 1994. Drug treatment in pregnancy. Curr. Opin. Obstet. Gynecol. 6:50-57.
16. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
17. Louie A, Heine HS, VanScoy B, Eichas A, Files K, Fikes S, Brown DL, Kinzig-Schippers M, Sorgel F, Drusano GL. 2011. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob. Agents Chemother. 55:822-830.
18. Louie A, Kim K, Brown D, VanScoy B, Kulawy R, Liu W, Kinzig-Schippers Sorgel F, Heine H, Drusano GL. 2007. Dose-ranging and dose-fractionation studies of moxifloxacin against Bacillus anthracis, abstr A-1442, p 36. Abstr. 47th Intersci Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
19. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920-4927.
20. Craig WA. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum antibiotics. Diagn. Microbiol. Infect. Dis. 22:89-96.
21. Salifi V, Amicosante G, Strom R. 1977. The inactivation of betalactamase I from B. cereus by dicloxacillin: effect of buffer composition on the kinetic characteristics of the modified enzyme. Ital. J. Biochem. 26:37-43.
22. Strom R, Ravagnan G, Salfi V. 1976. Inactivation of Bacillus cereus -lactamase by halogenated isoxazolylpenicillins. Eur. J. Biochem. 62:95-101.
23. Clinical and Laboratory Standards Institute. 2006. Methods for dilutional antimicrobial susceptibility testing for bacteria that grow aerobically: approved standard. CLSI document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Heine HS, Bassett J, Miller L, Hartings JM, Ivins BE, Pitt ML, Fritz D, Norris SL, Byrne WR. 2007. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob. Agents Chemother. 51:1373-1379.
25. Louie A, VanScoy BD, Brown DL, Kulawy RW, Heine HS, Drusano GL. 2012. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrob. Agents Chemother. 56:1229-1239.
26. Deziel MR, Heine H, Louie A, Kao M, Byrne WR, Basset J, Miller L, Bush K, Kelly M, Drusano GL. 2005. Effective antimicrobial agents for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
27. Louie A, Heine HS, Kim K, Brown DL, VanScoy B, Liu W, Kinzig-Schippers M, Sorgel F, Drusano GL. 2008. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob. Agents Chemother. 52:2486-2496.
28. Muller AE, DeJongh J, Oostvogel PM, Voskuyl RA, Dorr Joep Danhof M, Mouton JW. 2008. Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. Am. J. Obstet. Gynecol. 198:108.e6.
29. PDR Staff. 2007. Physicians' desk reference. Thomson PDR, Montevale, NJ.
30. Sjovall J, Alvan G, Westerlund D. 1985. Dose-dependent absorption of amoxicillin and bacampicillin. Clin. Pharmacol. Ther. 38:241-250.
31. Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP. 2008. Pharmacodynamic target attainment of oral -lactams for the empiric treatment of acute otitis media in children. Pediatr. Drugs 10:329-335.
32. D'Argenio DZ, Schumitzky A. 1997. ADAPT II. A program for simulations, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.usc.edu/.
33. Pham P, Bartlett JG. Johns Hopkins Point of Care Information Technology Center antibiotic guide: amoxicillin. http://www.hopkinsguides.com/hopkins/ub/ view/Johns-Hopkins-ABX-Guide/540017/all/Amoxicillin.
34. McConaghy JR. 2001. The evaluation and treatment of children with acute otitis media. J. Fam. Pract. 50:457-459.
35. Louie A, VanScoy BD, Heine HS, III, Liu W, Abshire T, Holman K, Kulawy R, Brown DL, Drusano GL. 2012. Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrob. Agents Chemother. 56:513-517.
36. Lightfoot NF, Scott RJ. Turnbull PC. 1990. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med. Bull. 68:95S-98S.
37. Paintaud G, Alvan G, Dahl ML, Grahnen A, Sjovall J, Svensson JO. 1992. Nonlinearlity of amoxicillin absorption kinetics in humans. Eur. J. Clin. Pharmacol. 43:283-288.
38. Mohammed MJ, Marston CK, Popovic T, Weyant RS, Tenover FC. 2002. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradiant diffusion methods. J. Clin. Microbiol. 40:1902-1907.